Table 1. Patients' characteristics.
patient | sex | age (y) | disease | stage | previous Tx | site of Bx | Bx to PET | PentixaforPET/CT | DOTATOCPET/CT | FDGPET/CT | CXCR4IRS | SSTR2IRS | SSTR5IRS |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | m | 69 | SCLC | ED | RCTx | primary | 2 months | + | + | n/a | 8 | 0 | 0 |
2 | f | 38 | SCLC | ED | none | metastasis | 1 week | − | n/a | + | 10 | 0 | 4 |
3 | m | 63 | SCLC | ED | RCTx | metastasis | 3 weeks | + | - | n/a | 4 | 0 | 4 |
4 | f | 62 | SCLC | ED | CTx | primary | 4 weeks | + | n/a | + | 4 | 0 | 0 |
5 | f | 49 | SCLC | LD | none | primary | 2 weeks | + | n/a | + | 0 | 0 | 0 |
6 | f | 74 | LCNEC | ED | RCTx | metastasis | 5 months | − | − | + | 12 | 0 | 0 |
7 | m | 63 | SCLC | ED | RCTx | metastasis | 2 weeks | + | − | n/a | 4 | 4 | 4 |
8 | m | 56 | SCLC | ED | RCTx | primary | 8 months | + | n/a | + | 8 | 0 | 0 |
9 | m | 79 | SCLC | ED | CTx | primary | 2 months | + | + | n/a | 3 | 4 | 0 |
10 | f | 67 | SCLC | LD | none | primary | 2 weeks | + | n/a | + | 4 | 4 | 0 |
All patients with relapsed disease had undergone 1st- and/or 2nd-line treatment (patients #1, #3, #9). 1st-line treatment included 2-6 cycles of platinum/etoposide-containing chemotherapy (patient #1: 2 cycles, patients #3 and #9: 4 cycles, patients #4, #6, #7 and #8: 6 cycles) (+radiotherapy), 2nd-line therapy had topotecan as the mainstay (all three patients [#1, #3 and #9] received 6 cycles).
Bx = biopsy; CTx = chemotherapy; IRS = immunoreactive score; LCNEC = large cell neuroendocrine carcinoma of the lung; LN = lymph node; N/A = not assessed; PD= primary diagnosis; RCTx = radio-chemotherapy; SCLC= small cell lung cancer; Tx = treatment.